Trials / Conditions / Secondary Central Nervous System Lymphoma (SCNSL)
Secondary Central Nervous System Lymphoma (SCNSL)
4 registered clinical trials studyying Secondary Central Nervous System Lymphoma (SCNSL) — 3 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL NCT07410520 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) NCT07082868 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022 | Nurix Therapeutics, Inc. | Phase 1 |
| Completed | Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central NCT03703167 | Memorial Sloan Kettering Cancer Center | Phase 1 |